Mervyn Israel

3.0k total citations
116 papers, 2.5k citations indexed

About

Mervyn Israel is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Mervyn Israel has authored 116 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Molecular Biology, 47 papers in Organic Chemistry and 47 papers in Oncology. Recurrent topics in Mervyn Israel's work include Cancer therapeutics and mechanisms (41 papers), Cancer Treatment and Pharmacology (34 papers) and Chemotherapy-induced cardiotoxicity and mitigation (24 papers). Mervyn Israel is often cited by papers focused on Cancer therapeutics and mechanisms (41 papers), Cancer Treatment and Pharmacology (34 papers) and Chemotherapy-induced cardiotoxicity and mitigation (24 papers). Mervyn Israel collaborates with scholars based in United States, Switzerland and France. Mervyn Israel's co-authors include Trevor W. Sweatman, Edward J. Modest, William J. Pegg, Emil Frei, Leonard Lothstein, R. Seshadri, Lynne C. Jones, Marc B. Garnick, M Potmĕsil and P M Wilkinson and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Molecular and Cellular Biology.

In The Last Decade

Mervyn Israel

113 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mervyn Israel United States 28 1.3k 822 608 513 209 116 2.5k
Karen R. Grotzinger United States 13 1.6k 1.2× 1.2k 1.4× 306 0.5× 566 1.1× 304 1.5× 18 3.3k
N R Bachur United States 22 992 0.8× 609 0.7× 402 0.7× 421 0.8× 82 0.4× 43 2.1k
Sergio Penco Italy 31 1.9k 1.5× 830 1.0× 1.1k 1.8× 274 0.5× 79 0.4× 93 3.1k
Anna Maria Casazza Italy 29 1.2k 0.9× 1.4k 1.7× 782 1.3× 420 0.8× 46 0.2× 80 2.9k
Giuseppe Cassinelli Italy 23 863 0.7× 396 0.5× 542 0.9× 278 0.5× 77 0.4× 48 1.7k
Miles P. Hacker United States 28 1.2k 0.9× 1.3k 1.5× 859 1.4× 123 0.2× 92 0.4× 106 3.0k
K M Tewey United States 7 3.3k 2.5× 1.4k 1.7× 712 1.2× 267 0.5× 70 0.3× 7 3.9k
Franco Zunino Italy 30 1.5k 1.2× 1.5k 1.8× 705 1.2× 103 0.2× 137 0.7× 73 3.1k
Fernando C. Giuliani Italy 21 731 0.6× 626 0.8× 300 0.5× 218 0.4× 41 0.2× 49 1.4k
Rosanna Supino Italy 37 3.0k 2.3× 1.7k 2.1× 593 1.0× 175 0.3× 105 0.5× 109 4.9k

Countries citing papers authored by Mervyn Israel

Since Specialization
Citations

This map shows the geographic impact of Mervyn Israel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mervyn Israel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mervyn Israel more than expected).

Fields of papers citing papers by Mervyn Israel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mervyn Israel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mervyn Israel. The network helps show where Mervyn Israel may publish in the future.

Co-authorship network of co-authors of Mervyn Israel

This figure shows the co-authorship network connecting the top 25 collaborators of Mervyn Israel. A scholar is included among the top collaborators of Mervyn Israel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mervyn Israel. Mervyn Israel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ahmed, N., et al.. (2012). Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. SHILAP Revista de lepidopterología. 9 indexed citations
2.
Hofmann, Polly A., Trevor W. Sweatman, Ganesh R. Panta, et al.. (2004). Cardioprotective effects of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate (AD 198). Cancer Research. 64. 258–259. 2 indexed citations
3.
Israel, Mervyn, et al.. (1998). Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.. PubMed. 10(4). 209–17. 6 indexed citations
4.
5.
Chuang, Linda F., Hsiang‐Fu Kung, Mervyn Israel, & Ronald Y. Chuang. (1992). Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32). Biochemical Pharmacology. 43(4). 865–872. 8 indexed citations
7.
Dass, Chhabil, Ramakrishnan Ayloor Seshadri, Mervyn Israel, & Dominic M. Desiderio. (1988). Fast atom bombardment mass spectrometric analysis of anthracyclines and anthracyclinones. Journal of Mass Spectrometry. 17(1). 37–45. 23 indexed citations
8.
Krishan, Awtar, et al.. (1988). Anthracycline-induced DNA breaks and resealing in doxorubicin-resistant murine leukemic P388 cells. Biochemical Pharmacology. 37(9). 1763–1772. 27 indexed citations
9.
Chuang, Linda F., et al.. (1984). Selective inhibition of eukaryotic RNA polymerase: A possible new mechanism of antitumor drug action. Biochemical and Biophysical Research Communications. 120(3). 946–952. 5 indexed citations
10.
Potmĕsil, M, S Kirschenbaum, Mervyn Israel, et al.. (1983). Relationship of adriamycin concentrations to the DNA lesions induced in hypoxic and euoxic L1210 cells.. PubMed. 43(8). 3528–33. 41 indexed citations
11.
Krishan, Awtar, Kamla Dutt, Mervyn Israel, & Ram Ganapathi. (1981). Comparative effects of adriamycin and N-trifluoroacetyladriamycin-14-valerate on cell kinetics, chromosomal damage, and macromolecular synthesis in vitro.. PubMed. 41(7). 2745–50. 30 indexed citations
12.
Krishan, Awtar & Mervyn Israel. (1979). Excitation and quantitation of adriamycin and related anthracyclines by laser flow cytometry. 1 indexed citations
13.
Garnick, Marc B., William D. Ensminger, & Mervyn Israel. (1979). A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin.. PubMed. 39(10). 4105–10. 64 indexed citations
14.
Krishan, Awtar, Ram Ganapathi, & Mervyn Israel. (1978). Effect of adriamycin and analogs on the nuclear fluorescence of propidium iodide-stained cells.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(11 Pt 1). 3656–62. 39 indexed citations
15.
Israel, Mervyn, P M Wilkinson, William J. Pegg, & Emil Frei. (1978). Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(2). 365–70. 41 indexed citations
16.
Israel, Mervyn, et al.. (1977). Hepatobiliary metabolism and excretion of adriamycin (ADR) in man [proceedings].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 4(5). 639P–639P. 3 indexed citations
17.
Krishan, Awtar, Mervyn Israel, Edward J. Modest, & Emil Frei. (1976). Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate.. PubMed. 36(6). 2108–9. 53 indexed citations
18.
Israel, Mervyn, Edward J. Modest, & Emil Frei. (1975). N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.. PubMed. 35(5). 1365–8. 113 indexed citations
19.
Israel, Mervyn, et al.. (1972). Cysteine scavengers. 1. Bis(3-pyridylmethyl) phosphate and bis(3-pyridylmethyl) pyrophosphate. Journal of Medicinal Chemistry. 15(3). 337–338. 1 indexed citations
20.
Israel, Mervyn, et al.. (1965). Pyrimidine Derivatives VII. Journal of Pharmaceutical Sciences. 54(11). 1626–1632. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026